15 research outputs found
A cooperação técnica OPAS-Brasil na formação de trabalhadores para a saúde (1973-1983)
Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
Aims The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p
Insights into the clinical and functional significance of cardiac autonomic dysfunction in Chagas disease
Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402
Histologic and functional alterations of human exocrine pancreas in Manson's schistosomiasis
Acidentes de trabalho graves e atividades produtivas nas regiões administrativas de saúde em Pernambuco: uma análise a partir da identificação de aglomerados produtivos locais
Ineficácia in vivo da terbinafina em leishmaniose cutânea causada por Leishmania (Leishmania) amazonensis em camundongos C57BL/6
Ultrastructural changes in the epidermis of petals of the sweet orange infected by Colletotrichum acutatum
Evolução intergeracional da estatura no Estado de Pernambuco, Brasil, entre 1945 e 2006: 2 - aspectos analíticos Intergenerational evolution of stature in Pernambuco State, Brazil (1945-2006): 2 - analytical aspects
Utilizando-se modelos de regressão multinível, foram identificados fatores relacionados à evolução estatural de pessoas residentes em Pernambuco, Brasil, em 2006 e nascidas a partir de 1945. Os dados provêm de dois inquéritos estaduais de base populacional. No modelo final de cada grupo etário, ano de nascimento, sexo, escolaridade, renda e residência em área urbana ficaram positivamente associadas ao crescimento estatural dos adultos, bem como de crianças e adolescentes de 5 a 19 anos. Nos menores de cinco anos, além dessas variáveis, também ficaram positivamente associados o peso ao nascer e a realização de pré-natal, enquanto a ocorrência de diarreia nas últimas duas semanas anteriores à entrevista mostrou associação negativa. Os resultados do estudo mostram que o crescimento estatural foi mais favorecido em ambientes nos quais predominaram melhores condições socioeconômicas e ambientais.<br>This study used multivariate regression models to identify factors associated with the height trend in residents of Pernambuco State, Brazil, in 2006, born from 1945 onward. The data were from two population-based statewide surveys. In the final model for each age bracket, year of birth, gender, schooling, and residence in urban areas were positively associated with stature in adults, as well as in children and adolescents 5 to 19 years of age. In children under five years, in addition to these variables, birth weight and prenatal care were also positively associated, while diarrhea in the two weeks prior to the interview showed a negative association. The findings show that stature was favored by settings with better socioeconomic and environmental conditions